CN106928341B - 定点单取代聚乙二醇化Exendin类似物及其制备方法 - Google Patents

定点单取代聚乙二醇化Exendin类似物及其制备方法 Download PDF

Info

Publication number
CN106928341B
CN106928341B CN201710091006.8A CN201710091006A CN106928341B CN 106928341 B CN106928341 B CN 106928341B CN 201710091006 A CN201710091006 A CN 201710091006A CN 106928341 B CN106928341 B CN 106928341B
Authority
CN
China
Prior art keywords
lys
gly
glu
dde
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201710091006.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106928341A (zh
Inventor
岳鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Benemae Pharmaceutical Corp
Original Assignee
Shanghai Benemae Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Benemae Pharmaceutical Corp filed Critical Shanghai Benemae Pharmaceutical Corp
Priority to CN201710091006.8A priority Critical patent/CN106928341B/zh
Publication of CN106928341A publication Critical patent/CN106928341A/zh
Application granted granted Critical
Publication of CN106928341B publication Critical patent/CN106928341B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201710091006.8A 2011-03-30 2011-03-30 定点单取代聚乙二醇化Exendin类似物及其制备方法 Active CN106928341B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710091006.8A CN106928341B (zh) 2011-03-30 2011-03-30 定点单取代聚乙二醇化Exendin类似物及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710091006.8A CN106928341B (zh) 2011-03-30 2011-03-30 定点单取代聚乙二醇化Exendin类似物及其制备方法
CN201110078314XA CN102718868A (zh) 2011-03-30 2011-03-30 定点单取代聚乙二醇化Exendin类似物及其制备方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201110078314XA Division CN102718868A (zh) 2011-03-30 2011-03-30 定点单取代聚乙二醇化Exendin类似物及其制备方法

Publications (2)

Publication Number Publication Date
CN106928341A CN106928341A (zh) 2017-07-07
CN106928341B true CN106928341B (zh) 2021-06-01

Family

ID=46929417

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710091006.8A Active CN106928341B (zh) 2011-03-30 2011-03-30 定点单取代聚乙二醇化Exendin类似物及其制备方法
CN201110078314XA Pending CN102718868A (zh) 2011-03-30 2011-03-30 定点单取代聚乙二醇化Exendin类似物及其制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201110078314XA Pending CN102718868A (zh) 2011-03-30 2011-03-30 定点单取代聚乙二醇化Exendin类似物及其制备方法

Country Status (10)

Country Link
US (1) US20140142037A1 (enExample)
EP (1) EP2692730B1 (enExample)
JP (1) JP6297969B2 (enExample)
KR (1) KR102005385B1 (enExample)
CN (2) CN106928341B (enExample)
AU (1) AU2012237899B2 (enExample)
BR (1) BR112013024706B1 (enExample)
CA (1) CA2829122C (enExample)
RU (1) RU2625015C2 (enExample)
WO (1) WO2012130015A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
KR101768446B1 (ko) * 2014-03-21 2017-08-17 애니젠 주식회사 신규한 엑세나타이드 유사체 및 그의 용도
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
GB201603510D0 (en) * 2016-02-29 2016-04-13 Univ Ulster Compositions for use in the treatment of neurological disease
CN115703825A (zh) * 2021-08-17 2023-02-17 派格生物医药(苏州)股份有限公司 艾塞那肽变体及其聚乙二醇缀合物的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1363559A (zh) * 2001-05-10 2002-08-14 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
CN1745091A (zh) * 2003-01-18 2006-03-08 派格斯菲尔有限公司 非靶位点胺基被保护的肽,其制备方法以及使用该肽制备特异性地结合的peg肽的方法
KR20070115602A (ko) * 2006-06-01 2007-12-06 이강춘 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도
CN101125207A (zh) * 2006-11-14 2008-02-20 上海华谊生物技术有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407936A (pt) * 2003-03-19 2006-02-21 Lilly Co Eli composto de glp-1 peguilado, método de estimular o receptor de glp-1 em um indivìduo, e, uso de composto glp-1 peguilado
WO2006037811A2 (en) * 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
WO2007061148A1 (en) * 2005-11-24 2007-05-31 Pegsphere Co., Ltd. Site-specific peg conjugates of glp-1 and methods for production thereof
WO2008130066A1 (en) * 2007-04-20 2008-10-30 Kang Choon Lee Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
US7935877B2 (en) * 2007-04-20 2011-05-03 Master Key, Llc System and method for music composition
AU2010225523B2 (en) * 2009-03-20 2012-05-24 Hanmi Science Co., Ltd. Method for preparing a site-specific physiologically active polypeptide conjugate
CN101870728A (zh) * 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
CN101559041B (zh) * 2009-05-19 2014-01-15 中国科学院过程工程研究所 粒径均一的多肽药物缓释微球或微囊制剂及制备方法
BR112012007374A2 (pt) * 2009-09-30 2019-09-24 Glaxo Group Ltd composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante
CN102397558B (zh) * 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Exendin-4类似物的定位聚乙二醇化修饰物及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1363559A (zh) * 2001-05-10 2002-08-14 上海华谊生物技术有限公司 促胰岛素分泌肽衍生物
CN1745091A (zh) * 2003-01-18 2006-03-08 派格斯菲尔有限公司 非靶位点胺基被保护的肽,其制备方法以及使用该肽制备特异性地结合的peg肽的方法
KR20070115602A (ko) * 2006-06-01 2007-12-06 이강춘 폴리에틸렌글리콜 또는 이의 유도체로 단일 수식된 엑센딘,이의 제조방법 및 이의 용도
CN101125207A (zh) * 2006-11-14 2008-02-20 上海华谊生物技术有限公司 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Preparation and PEGylation of exendin-4 peptide secreted from yeast Pichia pastoris;Jin Zhou et al.;《European Journal of Pharmaceutics and Biopharmaceutics》;20090207;第72卷;第412-417页 *
蛋白质和肽类分子的聚乙二醇化化学;姜忠义等;《有机化学》;20031231;第23卷(第12期);第1340-1347页 *

Also Published As

Publication number Publication date
CN106928341A (zh) 2017-07-07
RU2013147468A (ru) 2015-05-10
JP2014510735A (ja) 2014-05-01
CA2829122A1 (en) 2012-10-04
KR102005385B1 (ko) 2019-07-30
US20140142037A1 (en) 2014-05-22
BR112013024706B1 (pt) 2022-10-11
KR20140033023A (ko) 2014-03-17
AU2012237899A1 (en) 2013-09-19
CA2829122C (en) 2022-05-03
BR112013024706A2 (pt) 2016-09-06
EP2692730B1 (en) 2018-11-14
WO2012130015A1 (zh) 2012-10-04
EP2692730A1 (en) 2014-02-05
JP6297969B2 (ja) 2018-03-20
EP2692730A4 (en) 2015-04-01
RU2625015C2 (ru) 2017-07-11
CN102718868A (zh) 2012-10-10
AU2012237899B2 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
CN106928341B (zh) 定点单取代聚乙二醇化Exendin类似物及其制备方法
JP7250814B2 (ja) 新規ｇｌｐ－１類似体
TW201119670A (en) Sugar chain adduct of antigenicity GLP-1 analogue
WO2015149627A1 (zh) 结构修饰的glp-1类似物及其制备方法
AU2024310569A1 (en) Albumin bound macromolecule tri-agonist activating glp-1/gip/glucagon receptors
HK40103760A (en) Novel glp-1 analogues
HK40086836B (en) Novel glp-1 analogues
HK40086836A (en) Novel glp-1 analogues
HK40044876B (en) Novel glp-1 analogues
HK40044876A (en) Novel glp-1 analogues
EA049274B1 (ru) Новые аналоги glp-1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Fixed point monosubstituted pegylated exendin analogue and its preparation method

Effective date of registration: 20220222

Granted publication date: 20210601

Pledgee: Bank of Nanjing Limited by Share Ltd. Shanghai branch

Pledgor: SHANGHAI BENEMAE PHARMACEUTICAL Corp.

Registration number: Y2022310000032

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20231018

Granted publication date: 20210601

Pledgee: Bank of Nanjing Limited by Share Ltd. Shanghai branch

Pledgor: SHANGHAI BENEMAE PHARMACEUTICAL Corp.

Registration number: Y2022310000032